Product Information
KONVOMEP 2-84 MG/ML ORAL SUSP is a brand product labeled by Azurity Pharmaceuticals Inc., priced at $1.2442 per ML under NDC 65628027210. Its NADAC has been published 168 times since Jul 19, 2023.
FDA first approved this application on Aug 30, 2022.
Manufacturer
Azurity Pharmaceuticals Inc.NDC
65628027210
Classification
Brand
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
New Drug (NDA)
FDA Application
NDA213593FDA Approved
8/30/2022
On Market Since
2/15/2023
Price Statistics
The NADAC for KONVOMEP 2-84 MG/ML ORAL SUSP has been published 168 times since Jul 19, 2023, and over the history we have for it it has risen 13.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.2442 per ML |
|---|---|
| All-time high | $1.2519 (Jul 15, 2026) |
| All-time low | $1.1001 (Jul 19, 2023) |
| 52-week high | $1.2519 |
| 52-week low | $1.2110 |
| Median price | $1.2129 |
| Average price | $1.1767 |
| Largest weekly change | +9.0% (Jan 15, 2025) |
| Weeks tracked | 168 |
| Tracking since | Jul 19, 2023 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Azurity Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
omeprazole and sodium bicarbonate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of KONVOMEP 2-84 MG/ML ORAL SUSP?
The current National Average Drug Acquisition Cost (NADAC) for KONVOMEP 2-84 MG/ML ORAL SUSP, manufactured by Azurity Pharmaceuticals Inc., is $1.2442 per ML (NDC 65628027210), effective Sep 30, 2026.
How has the price of KONVOMEP 2-84 MG/ML ORAL SUSP changed over time?
Over the history we have for it, the NADAC for KONVOMEP 2-84 MG/ML ORAL SUSP has risen 13.1%. It has been tracked across 168 weekly CMS publications since Jul 19, 2023.
What are the highest and lowest recorded NADAC prices for KONVOMEP 2-84 MG/ML ORAL SUSP?
Since Jul 19, 2023, the NADAC for KONVOMEP 2-84 MG/ML ORAL SUSP has ranged from a low of $1.1001 (Jul 19, 2023) to a high of $1.2519 (Jul 15, 2026), with a median of $1.2129 per ML.
Are there cheaper alternatives to KONVOMEP 2-84 MG/ML ORAL SUSP?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as KONVOMEP 2-84 MG/ML ORAL SUSP in a comparable dosage form, but none are currently priced below it.
Who manufactures KONVOMEP 2-84 MG/ML ORAL SUSP?
KONVOMEP 2-84 MG/ML ORAL SUSP (NDC 65628027210) is labeled by Azurity Pharmaceuticals Inc., and CMS classifies it as a brand product.